Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion

被引：38

作者：

Porter, D

Levine, JE

机构：

[1] Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA

[2] Univ Penn, Ctr Med, Dept Med, Philadelphia, PA USA

来源：

SEMINARS IN HEMATOLOGY | 2006年 / 43卷 / 01期

关键词：

D O I：

10.1053/j.seminhematol.2005.09.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although dramatically effective for relapsed chronic myelogenous leukemia (CML), successful donor leukocyte infusion (DLI) remains limited primarily by inadequate responses for patients with diseases other than CML and by toxicity related to graft-versus-host disease (GVHD). Acute GVHD grades 2 to 4 follows 34% to 47% of infusions and chronic GVHD occurs in 33% to 61% of cases. Strategies to reduce the incidence and severity of GVHD while preserving the graft-versus-leukemia (GVL) effect, such as low-dose DLI, depletion of GVHD effector cells, and tumor-specific DLI, are reviewed. © 2006 Elsevier Inc. All rights reserved.

引用

收藏

页码：53 / 61

页数：9

相关论文

共 69 条

[1] Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion [J].

Akpek, G ;

Boitnott, JK ;

Lee, LA ;

Hallick, JP ;

Torbenson, M ;

Jacobsohn, DA ;

Arai, S ;

Anders, V ;

Vogelsang, GB .

BLOOD, 2002, 100 (12) :3903-3907

[2] Development of a prognostic model for grading chronic graft-versus-host disease [J].

Akpek, G ;

Zahurak, ML ;

Piantadosi, S ;

Margolis, J ;

Doherty, J ;

Davidson, R ;

Vogelsang, GB .

BLOOD, 2001, 97 (05) :1219-1226

[3] T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect [J].

Alyea, E ;

Weller, E ;

Schlossman, R ;

Canning, C ;

Webb, I ;

Doss, D ;

Mauch, P ;

Marcus, K ;

Fisher, D ;

Freeman, A ;

Parikh, B ;

Gribben, J ;

Soiffer, R ;

Ritz, J ;

Anderson, K .

BLOOD, 2001, 98 (04) :934-939

[4] Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant [J].

Alyea, EP ;

Soiffer, RJ ;

Canning, C ;

Neuberg, D ;

Schlossman, R ;

Pickett, C ;

Collins, H ;

Wang, YL ;

Anderson, KC ;

Ritz, J .

BLOOD, 1998, 91 (10) :3671-3680

[5]

ANTIN JH, 1992, BLOOD, V80, P2964

[6] High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions [J].

Badros, A ;

Barlogie, B ;

Morris, C ;

Desikan, R ;

Martin, SR ;

Munshi, N ;

Zangari, M ;

Toor, A ;

Cottler-Fox, M ;

Fassas, A ;

Aniassie, E ;

Schichman, S ;

Tricot, G .

BLOOD, 2001, 97 (09) :2574-2579

[7] TREATMENT OF MURINE LEUKAEMIA WITH X-RAYS AND HOMOLOGOUS BONE MARROW .2. [J].

BARNES, DWH ;

LOUTIT, JF .

BRITISH JOURNAL OF HAEMATOLOGY, 1957, 3 (03) :241-252

[8] Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematological malignancies [J].

Barrett, AJ ;

Malkovska, V .

BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (04) :754-761

[9] Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma [J].

Bernard, M ;

Dauriac, C ;

Drénou, B ;

Leberre, C ;

Branger, B ;

Fauchet, R ;

Le Prisé, PY ;

Lamy, T .

BONE MARROW TRANSPLANTATION, 1999, 23 (04) :329-333

[10] Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning [J].

Bethge, WA ;

Hegenbart, U ;

Stuart, MJ ;

Storer, BE ;

Maris, MB ;

Flowers, MED ;

Maloney, DG ;

Chauncey, T ;

Bruno, B ;

Agura, E ;

Forman, SJ ;

Blume, KG ;

Niederwieser, D ;

Storb, R ;

Sandmaier, BM .

BLOOD, 2004, 103 (03) :790-795

← 1 2 3 4 5 6 7 →